Cardiovascular medicine is entering a new era-an era where the stethoscope, angiogram, echocardiogram, catheterization laboratory, artificial intelligence, molecular biology, and genomic science are converging to redefine the way we understand, diagnose, treat, and prevent heart disease. Genomics in Cardiovascular Diseases: A Comprehensive Clinical Reference for Interventional Cardiologists is designed as a powerful clinical and research-focused guide for cardiologists, interventional cardiologists, physicians, fellows, residents, medical students, and cardiovascular researchers who want to understand the future of precision cardiovascular care.
For decades, cardiovascular diseases have been approached through symptoms, risk factors, imaging, laboratory parameters, and procedural findings. Hypertension, coronary artery disease, cardiomyopathy, arrhythmias, heart failure, dyslipidemia, sudden cardiac death, vascular disease, and thrombosis have traditionally been treated using population-based guidelines. But every patient is biologically unique. Two patients with the same angiographic lesion may have different disease progression. Two patients with similar cholesterol levels may have different genetic risks. Two patients receiving the same antiplatelet or statin therapy may respond differently. This difference is often hidden within the genome.
This book explores how genomic medicine is transforming cardiovascular practice from a generalized approach to a personalized, predictive, preventive, and precision-based model. It explains how inherited genetic variants, polygenic risk scores, pharmacogenomics, molecular pathways, epigenetics, gene expression, and advanced sequencing technologies are becoming increasingly relevant in daily cardiology practice. From familial hypercholesterolemia to hypertrophic cardiomyopathy, from long QT syndrome to dilated cardiomyopathy, from premature coronary artery disease to clopidogrel resistance, this book provides a practical framework for applying genomic knowledge in real-world cardiovascular decision-making.
The book also highlights the growing role of genomics in cath lab decision-making, antiplatelet therapy, lipid management, cardiomyopathy evaluation, inherited arrhythmia syndromes, aortic disease, thrombosis, and sudden cardiac death prevention.
A special focus is placed on pharmacogenomics in cardiovascular therapy, an area of rapidly growing importance. The book discusses how genetic variation can affect response to commonly used cardiovascular drugs including antiplatelet agents, anticoagulants, statins, beta-blockers, antihypertensives, antiarrhythmic drugs, and heart failure medications. For interventional cardiologists, understanding pharmacogenomics is especially important in patients undergoing PCI, stent implantation, complex coronary intervention, and long-term dual antiplatelet therapy. Personalized drug selection based on genomic insight may help improve safety, reduce adverse events, and enhance therapeutic success.
Genomics in Cardiovascular Diseases is not only a scientific reference-it is a clinical bridge between advanced research and patient care. It is written for readers who want to move beyond traditional risk factors and understand the deeper biological architecture of cardiovascular disease. Whether you are managing young patients with premature myocardial infarction, families with sudden cardiac death, patients with unexplained cardiomyopathy, resistant dyslipidemia, recurrent thrombosis, complex arrhythmias, or variable drug response after PCI, this book provides a structured and clinically meaningful approach.
